USD 136.25
(-0.67%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 2.73 Billion USD | 0.07% |
2022 | 2.73 Billion USD | 0.15% |
2021 | 2.72 Billion USD | 19.48% |
2020 | 2.28 Billion USD | 27.53% |
2019 | 1.79 Billion USD | -0.44% |
2018 | 1.79 Billion USD | -0.11% |
2017 | 1.8 Billion USD | -5.81% |
2016 | 1.91 Billion USD | 15.53% |
2015 | 1.65 Billion USD | -40.08% |
2014 | 2.76 Billion USD | 2.33% |
2013 | 2.69 Billion USD | 27.79% |
2012 | 2.11 Billion USD | 9.32% |
2011 | 1.93 Billion USD | -11.78% |
2010 | 2.19 Billion USD | -24.59% |
2009 | 2.9 Billion USD | 36.66% |
2008 | 2.12 Billion USD | 1.82% |
2007 | 2.08 Billion USD | 39.13% |
2006 | 1.5 Billion USD | 0.0% |
2005 | - USD | -100.0% |
2004 | 1.15 Billion USD | 0.0% |
2003 | 1.15 Billion USD | 0.0% |
2002 | 1.15 Billion USD | 0.0% |
2001 | - USD | 0.0% |
2000 | - USD | 0.0% |
1999 | - USD | 0.0% |
1998 | - USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 2.13 Billion USD | -16.4% |
2024 Q1 | 2.55 Billion USD | -6.58% |
2024 Q3 | 2.13 Billion USD | 0.05% |
2023 Q2 | 2.73 Billion USD | 0.0% |
2023 Q4 | 2.73 Billion USD | 0.04% |
2023 Q3 | 2.73 Billion USD | 0.04% |
2023 Q1 | 2.73 Billion USD | 0.0% |
2023 FY | 2.73 Billion USD | 0.07% |
2022 Q3 | 2.73 Billion USD | 0.07% |
2022 Q4 | 2.73 Billion USD | 0.04% |
2022 FY | 2.73 Billion USD | 0.15% |
2022 Q1 | 2.73 Billion USD | 0.04% |
2022 Q2 | 2.73 Billion USD | 0.0% |
2021 Q2 | 2.72 Billion USD | 24.81% |
2021 Q1 | 2.18 Billion USD | -4.33% |
2021 FY | 2.72 Billion USD | 19.48% |
2021 Q4 | 2.72 Billion USD | 0.04% |
2021 Q3 | 2.72 Billion USD | 0.04% |
2020 Q1 | 1.78 Billion USD | -0.22% |
2020 Q2 | 1.78 Billion USD | 0.06% |
2020 Q3 | 2.28 Billion USD | 27.68% |
2020 Q4 | 2.28 Billion USD | 0.04% |
2020 FY | 2.28 Billion USD | 27.53% |
2019 FY | 1.79 Billion USD | -0.44% |
2019 Q4 | 1.79 Billion USD | 38.41% |
2019 Q1 | 1.79 Billion USD | -0.06% |
2019 Q2 | 1.79 Billion USD | 0.0% |
2019 Q3 | 1.29 Billion USD | -28.03% |
2018 Q3 | 1.79 Billion USD | -0.06% |
2018 FY | 1.79 Billion USD | -0.11% |
2018 Q1 | 1.8 Billion USD | -0.06% |
2018 Q2 | 1.8 Billion USD | 0.0% |
2018 Q4 | 1.79 Billion USD | 0.0% |
2017 FY | 1.8 Billion USD | -5.81% |
2017 Q3 | 1.8 Billion USD | -0.06% |
2017 Q2 | 1.8 Billion USD | -0.06% |
2017 Q1 | 1.8 Billion USD | -5.7% |
2017 Q4 | 1.8 Billion USD | 0.0% |
2016 Q2 | 1.65 Billion USD | 0.06% |
2016 FY | 1.91 Billion USD | 15.53% |
2016 Q1 | 1.65 Billion USD | -0.12% |
2016 Q4 | 1.91 Billion USD | 15.74% |
2016 Q3 | 1.65 Billion USD | -0.12% |
2015 Q3 | 1.65 Billion USD | -0.06% |
2015 Q1 | 1.65 Billion USD | -39.97% |
2015 Q4 | 1.65 Billion USD | 0.0% |
2015 FY | 1.65 Billion USD | -40.08% |
2015 Q2 | 1.65 Billion USD | -0.12% |
2014 FY | 2.76 Billion USD | 2.33% |
2014 Q1 | 2.69 Billion USD | -0.15% |
2014 Q4 | 2.76 Billion USD | 26.64% |
2014 Q3 | 2.18 Billion USD | -19.01% |
2014 Q2 | 2.69 Billion USD | -0.07% |
2013 FY | 2.69 Billion USD | 27.79% |
2013 Q4 | 2.69 Billion USD | -0.07% |
2013 Q1 | 2.11 Billion USD | -0.05% |
2013 Q2 | 2.1 Billion USD | -0.24% |
2013 Q3 | 2.7 Billion USD | 28.25% |
2012 Q2 | 1.92 Billion USD | -0.16% |
2012 FY | 2.11 Billion USD | 9.32% |
2012 Q4 | 2.11 Billion USD | 23.22% |
2012 Q3 | 1.71 Billion USD | -11.01% |
2012 Q1 | 1.92 Billion USD | -0.16% |
2011 FY | 1.93 Billion USD | -11.78% |
2011 Q4 | 1.93 Billion USD | -10.89% |
2011 Q3 | 2.16 Billion USD | 1.12% |
2011 Q2 | 2.14 Billion USD | 0.28% |
2011 Q1 | 2.13 Billion USD | -2.37% |
2010 FY | 2.19 Billion USD | -24.59% |
2010 Q3 | 2.17 Billion USD | 56.28% |
2010 Q2 | 1.39 Billion USD | -1.21% |
2010 Q1 | 1.41 Billion USD | -51.45% |
2010 Q4 | 2.19 Billion USD | 0.6% |
2009 Q2 | 2.15 Billion USD | 0.0% |
2009 Q1 | 2.15 Billion USD | 1.36% |
2009 FY | 2.9 Billion USD | 36.66% |
2009 Q3 | 2.15 Billion USD | -0.05% |
2009 Q4 | 2.9 Billion USD | 34.88% |
2008 Q3 | 604 Million USD | -2.89% |
2008 Q2 | 622 Million USD | -0.64% |
2008 FY | 2.12 Billion USD | 1.82% |
2008 Q4 | 2.12 Billion USD | 251.82% |
2008 Q1 | 626 Million USD | -70.0% |
2007 Q2 | 1.5 Billion USD | 0.0% |
2007 Q4 | 2.08 Billion USD | 39.13% |
2007 FY | 2.08 Billion USD | 39.13% |
2007 Q1 | 1.5 Billion USD | 0.0% |
2007 Q3 | 1.5 Billion USD | 0.0% |
2006 Q1 | 1.5 Billion USD | 0.0% |
2006 FY | 1.5 Billion USD | 0.0% |
2006 Q4 | 1.5 Billion USD | 0.0% |
2006 Q3 | 1.5 Billion USD | 0.0% |
2006 Q2 | 1.5 Billion USD | 0.0% |
2005 Q3 | 1.15 Billion USD | 0.0% |
2005 Q4 | - USD | -100.0% |
2005 Q1 | 1.15 Billion USD | 0.0% |
2005 Q2 | 1.15 Billion USD | 0.0% |
2005 FY | - USD | -100.0% |
2004 Q2 | 1.15 Billion USD | 0.0% |
2004 Q1 | 1.15 Billion USD | 0.0% |
2004 FY | 1.15 Billion USD | 0.0% |
2004 Q3 | 1.15 Billion USD | 0.0% |
2004 Q4 | 1.15 Billion USD | 0.0% |
2003 FY | 1.15 Billion USD | 0.0% |
2003 Q4 | 1.15 Billion USD | 0.0% |
2003 Q3 | 1.15 Billion USD | 0.0% |
2003 Q1 | 1.15 Billion USD | 0.0% |
2003 Q2 | 1.15 Billion USD | 0.0% |
2002 Q2 | 1.15 Billion USD | 0.0% |
2002 Q3 | 1.15 Billion USD | 0.0% |
2002 Q4 | 1.15 Billion USD | 0.0% |
2002 FY | 1.15 Billion USD | 0.0% |
2002 Q1 | 1.15 Billion USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2001 Q3 | - USD | 0.0% |
2001 Q2 | - USD | 0.0% |
2001 FY | - USD | 0.0% |
2001 Q1 | - USD | 0.0% |
2000 Q1 | 554 Million USD | 0.0% |
2000 Q2 | - USD | -100.0% |
2000 Q3 | - USD | 0.0% |
2000 FY | - USD | 0.0% |
2000 Q4 | - USD | 0.0% |
1999 Q4 | - USD | 0.0% |
1999 FY | - USD | 0.0% |
1998 FY | - USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Editas Medicine, Inc. | 24.37 Million USD | -11121.894% |
Dynavax Technologies Corporation | 252.41 Million USD | -983.52% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -8138.944% |
Perrigo Company plc | 3.63 Billion USD | 24.714% |
Illumina, Inc. | 1.48 Billion USD | -83.68% |
Thermo Fisher Scientific Inc. | 31.3 Billion USD | 91.264% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -273400.0% |
Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 66.0% |
IQVIA Holdings Inc. | 12.95 Billion USD | 78.888% |
Heron Therapeutics, Inc. | 173.75 Million USD | -1474.074% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -1.188% |
Unity Biotechnology, Inc. | 23.53 Million USD | -11519.015% |
Waters Corporation | 2.3 Billion USD | -18.629% |
Biogen Inc. | 7.18 Billion USD | 61.952% |
Sangamo Therapeutics, Inc. | 33.51 Million USD | -8060.525% |
Evolus, Inc. | 120.35 Million USD | -2172.368% |
Adicet Bio, Inc. | 17.7 Million USD | -15349.359% |
Cara Therapeutics, Inc. | 37.07 Million USD | -7276.143% |
bluebird bio, Inc. | 224.41 Million USD | -1118.703% |
Esperion Therapeutics, Inc. | 501.54 Million USD | -445.314% |
FibroGen, Inc. | 89.69 Million USD | -2949.154% |
Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -84349.263% |
Homology Medicines, Inc. | 43.17 Million USD | -6234.538% |
Geron Corporation | 35.05 Million USD | -7702.916% |
Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | -16.729% |
Amicus Therapeutics, Inc. | 387.85 Million USD | -605.155% |
Myriad Genetics, Inc. | 130.9 Million USD | -1989.381% |
Viking Therapeutics, Inc. | 936 Thousand USD | -292100.855% |
Intellia Therapeutics, Inc. | 96.74 Million USD | -2726.961% |
Zoetis Inc. | 6.56 Billion USD | 58.333% |
Abeona Therapeutics Inc. | 4.4 Million USD | -62030.85% |
Mettler-Toledo International Inc. | 1.97 Billion USD | -38.442% |
BioMarin Pharmaceutical Inc. | 593.09 Million USD | -361.14% |
Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -277.398% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | -7899.415% |
Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -95.305% |
Atara Biotherapeutics, Inc. | 45.69 Million USD | -5885.6% |
Verastem, Inc. | 40.08 Million USD | -6722.831% |
Nektar Therapeutics | 112.62 Million USD | -2328.413% |
Axsome Therapeutics, Inc. | 178.07 Million USD | -1435.913% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -88872.023% |
Sarepta Therapeutics, Inc. | 1.13 Billion USD | -141.498% |
OPKO Health, Inc. | 222.03 Million USD | -1131.793% |
Exelixis, Inc. | 189.94 Million USD | -1339.898% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | -958.846% |
Corcept Therapeutics Incorporated | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 130.06 Million USD | -2002.795% |
Imunon, Inc. | 1.13 Million USD | -239961.161% |
Blueprint Medicines Corporation | 610.96 Million USD | -347.655% |
Insmed Incorporated | 1.19 Billion USD | -129.186% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | -82.425% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -4699.256% |
TG Therapeutics, Inc. | 100.11 Million USD | -2631.777% |
Incyte Corporation | 29.16 Million USD | -9278.643% |
Emergent BioSolutions Inc. | 446.5 Million USD | -512.542% |